An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry

NCT ID: NCT01892319

Last Updated: 2019-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2446 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-09-30

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is conducted in Europe and Asia. The purpose of the study (Diabetes Pregnancy Registry) is to evaluate the safety of treatment with insulin detemir in pregnant women with diabetes mellitus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All patients

insulin detemir

Intervention Type DRUG

Patients will be treated according to routine clinical practice at the discretion of the treating physician

other injectable antidiabetic treatment regimens

Intervention Type DRUG

Patients will be treated according to routine clinical practice at the discretion of the treating physician

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

insulin detemir

Patients will be treated according to routine clinical practice at the discretion of the treating physician

Intervention Type DRUG

other injectable antidiabetic treatment regimens

Patients will be treated according to routine clinical practice at the discretion of the treating physician

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria: - Informed consent obtained before any data collection - Woman with a positive pregnancy test - Diabetes mellitus type 1 or 2, diagnosed prior to conception - Currently treated with Levemir® or other injectable antidiabetic treatment(s) - Unchanged basal insulin or other injectable antidiabetic treatment product (for those not treated with basal insulin) 4 weeks prior to and following conception Exclusion Criteria: - Women who have been pregnant for more than 16 weeks at baseline visit will be excluded from the study
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novo Nordisk A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Global Clinical Registry (GCR, 1452)

Role: STUDY_DIRECTOR

Novo Nordisk A/S

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novo Nordisk Investigational Site

Zagreb, , Croatia

Site Status

Novo Nordisk Investigational Site

Pori, , Finland

Site Status

Novo Nordisk Investigational Site

Tampere, , Finland

Site Status

Novo Nordisk Investigational Site

Turku, , Finland

Site Status

Novo Nordisk Investigational Site

Angers, , France

Site Status

Novo Nordisk Investigational Site

Corbeil-Essonnes, , France

Site Status

Novo Nordisk Investigational Site

Lille, , France

Site Status

Novo Nordisk Investigational Site

Nîmes, , France

Site Status

Novo Nordisk Investigational Site

Paris, , France

Site Status

Novo Nordisk Investigational Site

Toulouse, , France

Site Status

Novo Nordisk Investigational Site

Valenciennes, , France

Site Status

Novo Nordisk Investigational Site

Bramsche, , Germany

Site Status

Novo Nordisk Investigational Site

Eisenach, , Germany

Site Status

Novo Nordisk Investigational Site

Essen, , Germany

Site Status

Novo Nordisk Investigational Site

Friedrichsthal, , Germany

Site Status

Novo Nordisk Investigational Site

Ludwigshafen, , Germany

Site Status

Novo Nordisk Investigational Site

Neuwied, , Germany

Site Status

Novo Nordisk Investigational Site

Speyer, , Germany

Site Status

Novo Nordisk Investigational Site

Stuttgart, , Germany

Site Status

Novo Nordisk Investigational Site

Sulzbach-Rosenberg, , Germany

Site Status

Novo Nordisk Investigational Site

Athens, , Greece

Site Status

Novo Nordisk Investigational Site

Nea Efkarpia - Thessaloniki, , Greece

Site Status

Novo Nordisk Investigational Site

Castlebar, , Ireland

Site Status

Novo Nordisk Investigational Site

Co. Donegal, , Ireland

Site Status

Novo Nordisk Investigational Site

Dublin, , Ireland

Site Status

Novo Nordisk Investigational Site

Galway, , Ireland

Site Status

Novo Nordisk Investigational Site

Petah Tikva, , Israel

Site Status

Novo Nordisk Investigational Site

Livorno, , Italy

Site Status

Novo Nordisk Investigational Site

Milan, , Italy

Site Status

Novo Nordisk Investigational Site

Padua, , Italy

Site Status

Novo Nordisk Investigational Site

Roma, , Italy

Site Status

Novo Nordisk Investigational Site

Roma, , Italy

Site Status

Novo Nordisk Investigational Site

Sant'Andrea Delle Fratte (PG), , Italy

Site Status

Novo Nordisk Investigational Site

Torino, , Italy

Site Status

Novo Nordisk Investigational Site

Trento, , Italy

Site Status

Novo Nordisk Investigational Site

Verona, , Italy

Site Status

Novo Nordisk Investigational Site

Alor Gajah, , Malaysia

Site Status

Novo Nordisk Investigational Site

Alor Star, , Malaysia

Site Status

Novo Nordisk Investigational Site

Alor Star, , Malaysia

Site Status

Novo Nordisk Investigational Site

Batu Caves, , Malaysia

Site Status

Novo Nordisk Investigational Site

Ipoh, , Malaysia

Site Status

Novo Nordisk Investigational Site

Ipoh, , Malaysia

Site Status

Novo Nordisk Investigational Site

Kuala Lumpur, , Malaysia

Site Status

Novo Nordisk Investigational Site

Kuala Lumpur, , Malaysia

Site Status

Novo Nordisk Investigational Site

Kuala Lumpur, , Malaysia

Site Status

Novo Nordisk Investigational Site

Putrajaya, , Malaysia

Site Status

Novo Nordisk Investigational Site

Seremban, , Malaysia

Site Status

Novo Nordisk Investigational Site

Seremban, , Malaysia

Site Status

Novo Nordisk Investigational Site

Amsterdam, , Netherlands

Site Status

Novo Nordisk Investigational Site

Apeldoorn, , Netherlands

Site Status

Novo Nordisk Investigational Site

Arnhem, , Netherlands

Site Status

Novo Nordisk Investigational Site

Eindhoven, , Netherlands

Site Status

Novo Nordisk Investigational Site

Utrecht, , Netherlands

Site Status

Novo Nordisk Investigational Site

Ålesund, , Norway

Site Status

Novo Nordisk Investigational Site

Bergen, , Norway

Site Status

Novo Nordisk Investigational Site

Gjøvik, , Norway

Site Status

Novo Nordisk Investigational Site

Hamar, , Norway

Site Status

Novo Nordisk Investigational Site

Lillehammer, , Norway

Site Status

Novo Nordisk Investigational Site

Moss, , Norway

Site Status

Novo Nordisk Investigational Site

Tønsberg, , Norway

Site Status

Novo Nordisk Investigational Site

Legnica, , Poland

Site Status

Novo Nordisk Investigational Site

Lodz, , Poland

Site Status

Novo Nordisk Investigational Site

Lubin, , Poland

Site Status

Novo Nordisk Investigational Site

Poznan, , Poland

Site Status

Novo Nordisk Investigational Site

Poznan, , Poland

Site Status

Novo Nordisk Investigational Site

Szczecin, , Poland

Site Status

Novo Nordisk Investigational Site

Almada, , Portugal

Site Status

Novo Nordisk Investigational Site

Amadora, , Portugal

Site Status

Novo Nordisk Investigational Site

Leiria, , Portugal

Site Status

Novo Nordisk Investigational Site

Lisbon, , Portugal

Site Status

Novo Nordisk Investigational Site

Lisbon, , Portugal

Site Status

Novo Nordisk Investigational Site

Porto, , Portugal

Site Status

Novo Nordisk Investigational Site

Porto, , Portugal

Site Status

Novo Nordisk Investigational Site

Timișoara, Timiș County, Romania

Site Status

Novo Nordisk Investigational Site

Bucharest, , Romania

Site Status

Novo Nordisk Investigational Site

Bucharest, , Romania

Site Status

Novo Nordisk Investigational Site

Bucharest, , Romania

Site Status

Novo Nordisk Investigational Site

Bucharest, , Romania

Site Status

Novo Nordisk Investigational Site

Galati, , Romania

Site Status

Novo Nordisk Investigational Site

Barcelona, , Spain

Site Status

Novo Nordisk Investigational Site

Barcelona, , Spain

Site Status

Novo Nordisk Investigational Site

Madrid, , Spain

Site Status

Novo Nordisk Investigational Site

Málaga, , Spain

Site Status

Novo Nordisk Investigational Site

Seville, , Spain

Site Status

Novo Nordisk Investigational Site

Valencia, , Spain

Site Status

Novo Nordisk Investigational Site

Bath, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Belfast, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Bristol, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Devon, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Glasgow, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Inverness, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Southampton, , United Kingdom

Site Status

Novo Nordisk Investigational Site

Stevenage, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Croatia Finland France Germany Greece Ireland Israel Italy Malaysia Netherlands Norway Poland Portugal Romania Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Mathiesen ER, Andersen H, Kring SI, Damm P. Design and rationale of a large, international, prospective cohort study to evaluate the occurrence of malformations and perinatal/neonatal death using insulin detemir in pregnant women with diabetes in comparison with other long-acting insulins. BMC Pregnancy Childbirth. 2017 Jan 18;17(1):38. doi: 10.1186/s12884-016-1177-4.

Reference Type RESULT
PMID: 28100192 (View on PubMed)

Thorius IH, Petersen J, Husemoen LLN, Alibegovic AC, Gall MA, Damm P, Mathiesen ER. Glycemic Control and Risk of Congenital Malformations in Women With Type 1 Diabetes. Obstet Gynecol. 2024 Nov 1;144(5):725-732. doi: 10.1097/AOG.0000000000005722. Epub 2024 Sep 5.

Reference Type DERIVED
PMID: 39236320 (View on PubMed)

Mathiesen ER, Ali N, Alibegovic AC, Anastasiou E, Cypryk K, de Valk H, Dores J, Dunne F, Gall MA, Garcia SD, Hanaire HP, Husemoen LLN, Ivanisevic M, Kempe HP, McCance DR, Damm P. Risk of Major Congenital Malformations or Perinatal or Neonatal Death With Insulin Detemir Versus Other Basal Insulins in Pregnant Women With Preexisting Diabetes: The Real-World EVOLVE Study. Diabetes Care. 2021 Sep;44(9):2069-2077. doi: 10.2337/dc21-0472. Epub 2021 Jul 30.

Reference Type DERIVED
PMID: 34330786 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://novonordisk-trials.com

Clinical Trials at Novo Nordisk

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1132-9442

Identifier Type: OTHER

Identifier Source: secondary_id

ENCEPP/SDPP/4137

Identifier Type: REGISTRY

Identifier Source: secondary_id

NN304-4016

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.